Effect of Yunnan Hongyao Capsules in the treatment of patients with retinal vein obstruction of qi stagnation and blood stasis and Qi-Yin deficiency syndrome
SHI Yinjuan1 WU Huqiang2 LI Yuanbi2 LI Wenjun2 LI Yueming2 XIA Zemei2▲
1.Department of Ophthalmology, Anning First People’s Hospital, Yunnan Province, Anning 650300, China; 2.Department of Ophthalmology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Yunnan Province, Kunming 650000, China
Abstract：Objective To explore the effect of Yunnan Hongyao Capsules in treating patients with retinal vein obstruction of Qi stagnation and blood stasis and Qi-Yin deficiency syndrome. Methods Fifty hospitalized patients with retinal vein occlusion and fundus hemorrhage admitted to the Department of Ophthalmology, Yunnan Provincial Hospital of Traditional Chinese Medicine from June 2019 to May 2020 were divided into control group and experimental group according to random number table method, with 25 cases in each group. The control group and the experimental group were treated with Calcium Hydroxybenzene Sulfonate and Yunnan Hongyao Capsules respectively. The visual acuity level, fundus condition, macular edema, overall treatment effect, and coagulation function indexes were compared between the two groups. Results After treatment, the visual acuity level of the two groups were higher than those before treatment, while that of the experimental group was higher than that of the control group, and the differences were statistically significant (P＜0.05). The improvement of fundus in experimental group was better than that in control group, and the difference was statistically significant (P＜0.05). After treatment, macular edema in the two groups were lower than before treatment, while that of the experimental group was lower than that of the control group, and the differences were statistically significant (P＜0.05). The overall treatment effect of the experimental group was better than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, the thrombin time, activated partial thrombin time, and prothrombin time of the two groups were shorter than before treatment, and the fibrinogen time was lower than before treatment, while the thrombin time, activated partial thrombin time, and prothrombin time of the experimental group were longer than those of the control group, and the fibrinogen time of the experimental group was higher than that of the control group, and the differences were statistically significant (P＜0.05). Conclusion In the treatment of fundus hemorrhage with retinal vein obstruction, Yunnan Hongyao Capsules combined with Calcium Hydroxybenzene Sulfonate can effectively improve the visual acuity level, fundus condition, and coagulation function index, thereby reducing the thickness of macular fovea and improving the therapeutic effect.
史银娟1 吴虎强2 李苑碧2 李文君2 李月明2 夏泽梅2▲. 云南红药胶囊治疗气滞血瘀、气阴两虚证视网膜静脉阻塞患者眼底的效果[J]. 中国医药导报, 2023, 20(30): 130-133.
SHI Yinjuan1 WU Huqiang2 LI Yuanbi2 LI Wenjun2 LI Yueming2 XIA Zemei2▲. Effect of Yunnan Hongyao Capsules in the treatment of patients with retinal vein obstruction of qi stagnation and blood stasis and Qi-Yin deficiency syndrome. 中国医药导报, 2023, 20(30): 130-133.
[1] 胥静，吴烈.视网膜静脉阻塞黄斑水肿的发病机制及治疗进展[J].现代中医临床，2018，25（2）：50-54. [2] 刘朋朋，徐芳，冉静，等.羟苯磺酸钙联合康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床效果[J].农垦医学，2021，43（3）：228-231. [3] Liu JW，Yong-Zheng HE，Ofgastroenterology D. Clinical observation of Yunnanbaiyao capsule in treatment of upper gastrointestinal ulcer bleeding [J]. Journal of China Prescription Drug，2018. [4] 佚名.《现代眼科手册》一书出版[J].临床眼科杂志，2015（2）：101. [5] 武丹蕾，樊冬生，陈红娟，等.止血祛瘀明目片治疗视网膜静脉阻塞眼底出血瘀血伤络，阴虚内热证的多中心随机双盲对照临床研究[J].中国中西医结合杂志，2021，41（1）：35-40. [6] Nawar A，Shafik H. Efficacy and safety of Ziv-aflibercept in patients with central retinal vein occlusion [J]. J Ophthalmol，2021，22（1）：49. [7] 王圆月，刘军，张向立.和血明目片联合卵磷脂络合碘治疗视网膜静脉阻塞的临床研究[J].现代药物与临床，2021，36（12）：2587-2591. [8] 施煜珊.血塞通软胶囊对于视网膜分支静脉阻塞患者的眼底形态学影响[J].饮食保健，2020，74（47）：36. [9] Li Z，Guo C，Nie D，et al. Development and Evaluation of a Deep Learning System for Screening Retinal Hemorrhage Based on Ultra-Widefield Fundus Images [J]. Transl Vis Sci Techn，2020，9（2）：3. [10] 安利娜.复方血栓通胶囊辅助羟苯磺酸钙片治疗非增殖期糖尿病视网膜病变的疗效及对视网膜血流动力学的影响[J].实用糖尿病杂志，2021，17（1）：127-128. [11] 周瑞，陈娟，林思勇.视网膜分支静脉阻塞继发黄斑水肿玻璃体注射雷珠单抗不同治疗方案的疗效对比[J].眼科，2020，29（1）：63-67. [12] Mcallister IL，Smithies LA，Chen FK，et al. Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab com- pared with ranibizumab monotherapy [J]. BMJ Open Ophthalmology，2021，6（1）：e000728. [13] 赵通，张利，尹癑，等.玻璃体内注射康柏西普联合后筋膜囊注射曲安奈德对视网膜中央静脉阻塞继发顽固性黄斑水肿患者的治疗效果[J].眼科新进展，2020，40（4）：369-372. [14] 焦娟芳.云南红药胶囊对视网膜静脉阻塞的有效性及安全性[J].北方药学，2019，16（5）：163-164. [15] 吴改萍，谢立科，郝晓凤，等.从五行学说探讨视网膜静脉阻塞治疗思路[J].中国中医眼科杂志，2021，31（7）：504-507. [16] 周家林.OCTA技术在视网膜静脉阻塞治疗前后的应用研究进展[J].现代医药卫生，2021，37（17）：2955-2959. [17] 王文卓.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].中国医药指南，2018，16（8）：8-9. [18] 陈兰.视网膜静脉阻塞继发黄斑水肿的抗VEGF治疗方案的研究进展[J].眼科学报，2021，36（5）：371-379. [19] 刘瑞宝，霍勤.中药治疗视网膜静脉阻塞用药规律的探讨[J].光明中医，2018，33（3）：336-338. [20] 农吉晓，黄慕槿，唐勇华，等.中医药治疗视网膜静脉阻塞的用药规律研究[J].大众科技，2022，24（1）：115-119. [21] 郝壮，王珏，冀帅飞，等.抗VEGF药物联合皮质类固醇激素治疗视网膜静脉阻塞性黄斑水肿的Meta分析[J]. 国际眼科杂志，2021，21（1）：99-105. [22] 闫桦，叶志强.曲安奈德治疗视网膜静脉阻塞患者的效果观察[J].健康必读，2021，67（14）：62. [23] 安宁，杨相颖，张福燕，等.视网膜静脉阻塞的药物治疗进展[J].世界临床药物，2021，42（4）：314-320. [24] 李婧，刘素勤，谢爱宏，等.红花注射液穴位离子导入联合康柏西普治疗视网膜静脉阻塞并黄斑水肿的临床效果[J].中国当代医药，2023，30（5）：126-129，133. [25] 吴勤，朱卫星，杨春林.和血明目片联合雷珠单抗治疗RVO伴黄斑水肿的临床研究[J].中外医学研究，2022， 20（27）：131-134. [26] 刘文革，李萍萍，廖武.阿柏西普和雷珠单抗对视网膜静脉阻塞患者疗效的比较[J].中国医学创新，2023，20（6）：37-41. [27] 李果，陈颖，严宏.视网膜静脉阻塞并发黄斑水肿的联合药物治疗进展[J].国际眼科杂志，2019，19（2）：252- 255. [28] 褚梦琪.视网膜静脉阻塞继发黄斑水肿的最新治疗进展[J].中华实验眼科杂志，2018，36（1）：65-69.
2023, Vol. 20 
京公网安备 11010502046598号